Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

International Stem Cell (ISCO) Change in Account Payables (2016 - 2025)

International Stem Cell (ISCO) has disclosed Change in Account Payables for 16 consecutive years, with -$132000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Account Payables fell 135.71% to -$132000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$56000.0, a 411.11% decrease, with the full-year FY2024 number at -$178000.0, down 523.81% from a year prior.
  • Change in Account Payables was -$132000.0 for Q3 2025 at International Stem Cell, down from -$60000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $271000.0 in Q1 2025 to a low of -$161000.0 in Q2 2022.
  • A 5-year average of -$5000.0 and a median of -$28000.0 in 2023 define the central range for Change in Account Payables.
  • Biggest YoY gain for Change in Account Payables was 6875.0% in 2025; the steepest drop was 452.94% in 2025.
  • International Stem Cell's Change in Account Payables stood at -$103000.0 in 2021, then surged by 45.63% to -$56000.0 in 2022, then surged by 208.93% to $61000.0 in 2023, then crashed by 321.31% to -$135000.0 in 2024, then grew by 2.22% to -$132000.0 in 2025.
  • Per Business Quant, the three most recent readings for ISCO's Change in Account Payables are -$132000.0 (Q3 2025), -$60000.0 (Q2 2025), and $271000.0 (Q1 2025).